Buspirone in ADHD
Phase 2
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder.Disturbance of activity and attention
- Registration Number
- IRCT138901292000N3
- Lead Sponsor
- Behavioral Sciences and Research Center of Shahid Beheshti University of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
ADHD diagnosis according to DSM-VI criteria that scored above 20 in ADHD-Rating Scale. Exclusion criteria: evidence of a mental retardation or a major psychiatric problem other than oppositional defiant disorder and conduct disorder or receiving any psychotropic medication through 2 weeks before initiating treatment; medical disorders that would preclude the safe use of methylphenidate or buspirone.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hyperactivity, impulsivity and inattention symptoms according to parent and teacher point of view. Timepoint: baseline, 2, 4 and 6 weeks after the medications started. Method of measurement: ADHD Rating Scale,(parent and teacher form).
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: every 2 weeks. Method of measurement: check list.